Sulfobutyl Beta CyclodextrinProduct Introduction

1. Product Introduction

Sulfobutyl Beta Cyclodextrin is an anionic cyclodextrin derivative modified with sulfobutyl ether groups, synthesized via chemical grafting based on natural β-cyclodextrin. It has a truncated cone structure with hydrophilic exterior and hydrophobic inner cavity. It can form reversible inclusion complexes with drugs through van der Waals force and hydrophobic interaction, solving common problems of raw drugs including poor water solubility, photothermal degradation, hemolysis and nephrotoxicity. Compared with unmodified β-cyclodextrin, it owns greatly improved water solubility, biosafety and lower hemolytic risk. It is compatible with various hydrophobic anti-tumor, anti-inflammatory and antifungal compounds, acting as high-standard pharmaceutical inclusion carrier and stabilizer suitable for injection, oral and external preparations.

2. Application Scenarios

It has wide applications in pharmaceutical industry. In clinical preparations, it serves as key solubilizer for injectable drugs such as voriconazole and chemotherapeutics to replace irritant organic solvents. It can also be applied in oral, ophthalmic and topical preparations to enhance dissolution, mask bitter taste and reduce irritation. For chronic disease formulations, it supports sustained-release delivery systems. In scientific research, it is an essential experimental material for targeted delivery, nano-drug carriers and chiral separation to innovate novel preparations.

3. Future Research Directions

Future research will optimize controllable synthesis of substitution degree to precisely regulate inclusion capacity, reduce impurities and improve batch consistency. Composite functional modification combining targeting and pH-responsive properties will be developed to expand intelligent delivery applications. We will develop low-cost mass production technology to realize industrial transformation of lab formulas, explore new fields including biological preparations and cosmetic raw materials, and accelerate domestic substitution of high-end pharmaceutical excipients.